GSK Secures FDA Approval for First Oral Carbapenem in Complicated UTIs

The U.S. Food and Drug Administration has approved GSK’s oral antibiotic Utebzi for the treatment of complicated urinary tract infections, including pyelonephritis, in certain adult patients.

The approval is significant because Utebzi, also known as tebipenem pivoxil, is the first oral carbapenem antibiotic approved in the United States. It is intended for adults with complicated UTIs who have limited or no alternative oral treatment options.

Complicated UTIs are more serious than routine urinary tract infections. They can involve the kidneys, occur in patients with underlying medical risk factors, and carry a higher risk of treatment failure, hospitalization and severe outcomes. These infections are also increasingly difficult to treat when caused by bacteria resistant to commonly used antibiotics.

Until now, carbapenem antibiotics have generally been available only as intravenous treatments. This has meant that patients who require this powerful class of antibiotics often need to remain in hospital, attend infusion centers or receive home IV therapy. An effective oral option could offer physicians more flexibility, particularly for stable patients who may be able to complete treatment outside the hospital setting.

The approval was supported by the Phase III PIVOT-PO trial, which compared oral tebipenem pivoxil with intravenous imipenem-cilastatin in hospitalized adults with complicated UTIs, including pyelonephritis. The study showed that the oral therapy was non-inferior to the IV comparator, meaning it performed similarly on the trial’s key efficacy measure.

For clinicians, the approval may help address a long-standing treatment gap. While IV antibiotics remain essential for many serious infections, the lack of oral carbapenem options has created practical challenges for patients, physicians and healthcare systems. A new oral therapy could support earlier discharge, reduce dependence on infusion-based care and improve convenience for appropriate patients.

However, the approval also comes with an important antimicrobial stewardship message. Carbapenems are powerful antibiotics that are often reserved for resistant infections. The availability of an oral option does not mean it should be used broadly or casually. Careful prescribing will be essential to preserve its effectiveness and reduce the risk of further resistance.

For patients, this could represent a meaningful shift in the treatment of certain complicated UTIs. For healthcare systems, it highlights the urgent need for continued antibiotic innovation at a time when antimicrobial resistance remains one of the most pressing public health threats worldwide.

GSK has said Utebzi is expected to become available to U.S. patients by the end of 2026. Its real-world impact will depend not only on clinical adoption, but also on how carefully physicians, hospitals and payers position it within treatment guidelines and stewardship programs.

The approval is an important reminder that antibiotic development is still critical. As resistant infections continue to challenge healthcare systems, new treatment options must be matched with responsible use, careful monitoring and a continued commitment to protecting the effectiveness of existing therapies.

G-Med excels in HCP marketing by blending digital innovation with data-driven insights, creating an effective platform for reaching healthcare professionals, offering various advertising solutions. By using G-Med to engage HCPs, share data reports, and explore innovative channels, marketers can deliver targeted, impactful messages that foster strong connections. G-Med’s approach ensures that each campaign is tailored, scientifically rigorous, and effective, aligning perfectly with the best practices for successful HCP marketing.   

Contact us today to learn more: Contact@g-med.com